

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Lyon Joseph Douglas</u> (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE (Street) MENLO PARK CA 94025 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC [CORT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Chief Accounting Officer _____ Other (specify below) _____
	3. Date of Earliest Transaction (Month/Day/Year) 12/30/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/30/2020		M ⁽¹⁾		4,167	A	\$3.88	4,167	D	
Common Stock	12/30/2020		M ⁽¹⁾		20,833	A	\$8.27	25,000	D	
Common Stock	12/30/2020		S		25,000	D	\$26.0701 ⁽²⁾	0	D	
Common Stock	01/04/2021		M ⁽¹⁾		25,000	A	\$8.27	25,000	D	
Common Stock	01/04/2021		S		25,000	D	\$26.1338 ⁽³⁾	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$3.88	12/30/2020		M ⁽¹⁾			4,167	(4)	02/26/2026	Common Stock	4,167	\$0.00	0	D	
Stock Option (Right to Buy)	\$8.27	12/30/2020		M ⁽¹⁾			20,833	(5)	02/10/2027	Common Stock	20,833	\$0.00	79,167	D	
Stock Option (Right to Buy)	\$8.27	01/04/2021		M ⁽¹⁾			25,000	(5)	02/10/2027	Common Stock	25,000	\$0.00	54,167	D	

Explanation of Responses:

- These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$26.05 to \$26.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$26.05 to \$26.335 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- Fully exercisable.
- Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2021.

Remarks:

/s/ G. Charles Robb, Attorney-in-Fact for Joseph Douglas 01/04/2021
Lyon

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.